Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs ArcelorMittal SA — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.57 (market cap $6.04B), while ArcelorMittal SA trades at $64.18 (market cap $45.70B). The key difference: ArcelorMittal SA is far larger — about 7.6× Iovance Biotherapeutics Inc. Common Stock's market cap, and ArcelorMittal SA pays a 0.98% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and ArcelorMittal SA for 36 Days on average.
| IOVA | MT | |
|---|---|---|
Market Cap | $6.04B | $45.70B |
Volume | 14,805,993 | 1,964,621 |
Sector | Health | Basic Materials |
52-Week High | $14.82 | $78.74 |
52-Week Low | $1.81 | $36.91 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $5.97B | $55.27B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ArcelorMittal (MT) trades at $62.32, down 4.4% on the day, amid a bearish technical setup and recent operational disruptions in Ukraine. The stock shows mixed fundamentals with a low P/S of 0.75 and P/B of 0.84, but profitability metrics like net margin (2.88%) and ROE (3.32%) remain modest. Recent Q2 2026 earnings missed estimates, though Q1 and Q4 2025 beat expectations. Analyst consensus is bullish with a $74.33 price target, but technical indicators signal caution.
The outlook is clouded by near-term headwinds including the Ukraine plant impairment and volatile steel demand, yet long-term value is supported by low valuation multiples and strategic regionalization efforts. Risks include geopolitical exposure and cyclical industry pressures, but institutional sentiment remains positive with 52% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
